TITLE:
Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus

CONDITION:
Gastric Cancer

INTERVENTION:
T900607-sodium intravenous

SUMMARY:

      This is a clinical research study of T900607-sodium to determine if it is effective and safe
      in treating gastric cancer and adenocarcinoma of the esophagus. Patients will be treated on
      a weekly basis with an intravenous injection of the study drug.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          -  Histologically or cytologically confirmed diagnosis of gastric cancer or
             adenocarcinoma of the esophagus

          -  Subjects must have received 1-2 regimens of prior chemotherapy

          -  At least 18 years of age

          -  Bidimensionally measurable disease amenable to CT scanning. At least one lesion must
             be least 1 X 1 cm in size.

          -  Karnofsky performance status of at least 70%

          -  Estimated life expectancy of at least 12 weeks

          -  Females of childbearing potential must have a negative pregnancy test and agree to
             use an effective contraceptive

          -  Subject must be able to comply with study procedures and follow-up examinations.

          -  Signed written informed consent

          -  Lab Values (obtained  7 days prior to study enrollment):

               -  ANC at least 1.5x10e9/L, * Platelet count at least 100x10e9/L,

               -  Creatinine within 2 times upper limit of normal * AST and ALT within 5 times
                  upper limit of normal

               -  Bilirubin within 1.5 times upper limit of normal

               -  Albumin great than 2.5 g/dL

        Exclusion Criteria

          -  Severe, concurrent disease, infection or co-morbidity that, in the judgment of the
             investigator, would make the subject inappropriate for enrollment

          -  NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%,
             or acute anginal symptoms

          -  Patients who have received any investigational agent within 4 weeks of enrollment

          -  Patients who are pregnant or breast-feeding

          -  History of prior malignancy other than gastric cancer or adenocarcinoma of the
             esophagus within the last 5 years, except for adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  History of central nervous system metastases or carcinomatous meningitis

          -  Major surgery within 4 weeks of enrollment
      
